



ESME Metastatic Breast Cancer

**Publications
Referenced in PubMed**

Health Data & Partnerships

Publications 2016

1. Paclitaxel plus bevacizumab or paclitaxel as first-line treatment for HER2-negative metastatic breast cancer in a multicenter national observational study
Delaloge S, Perol D, Courtinard C, Brain E, Asselain B, Bachelot T, Debled M, Dieras V, Campone M, Levy C, Jacot W, Lorgis V, Veyret C, Dalenc F, Ferrero JM, Uwer L, Kerbrat P, Goncalves A, Mouret-Reynier MA, Petit T, Jouannaud C, Vanlemmens L, Chenuc G, Guesmia T, Robain M, Cailliot C.
Ann Oncol. 2016;27(9):1725-32. <https://doi.org/10.1093/annonc/mdw260>
2. Routinely collected data may usefully supplement Randomised controlled data on treatment effects for mortality
Pérol D, Robain M, Delaloge S, Cailliot C.
BMJ. 2016;355:i6745. <https://doi.org/10.1136/bmj.i6745>

Publications 2018

3. Endocrine therapy or chemotherapy as first-line therapy in hormone receptor–positive HER2-negative metastatic breast cancer patients.
Jacquet E, Lardy-Cléaud A, Pistilli B, Franck S, Cottu P, Delalogue S, Debled M, Vanlemmens L, Leheurteur M, Guizard AV, Laborde L, Uwer L, Jacot W, Berchery D, Desmoulin I, Ferrero JM, Perrocheau G, Courtinard C, Brain E, Chabaud S, Robain M, Bachelot T.
Eur J Cancer. 2018;95:93-101. <https://doi.org/10.1016/j.ejca.2018.03.013>

4. Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort.
Gobbini E, Ezzalfani M, Dieras V, Bachelot T, Brain E, Debled M, Jacot W, Mouret-Reynier MA, Goncalves A, Dalenc F, Patsouris A, Ferrero JM, Levy C, Lorgis V, Vanlemmens L, Lefeuvre-Plesse C, Mathoulin-Pelissier S, Petit T, Uwer L, Jouannaud C, Leheurteur M, Lacroix-Triki M, Lardy-Cleaud A, Robain M, Courtinard C, Cailliot C, Perol D, Delalogue S.
Eur J Cancer. 2018;96:17-24. <https://doi.org/10.1016/j.ejca.2018.03.015>

Publications 2019 (1/3)

5. Oral etoposide in heavily pre-treated metastatic breast cancer: results from the ESME cohort and comparison with other chemotherapy regimens.
Cabel L, Carton M, Cheaib B, Pierga J-Y, Dalenc F, Mailliez A, Levy C, Jacot W, Debled M, Leheurteur M, Desmoulins I, Lefeuvre C, Goncalves A, Uwer L, Ferrero JM, Eymard JC, Petit T, Mouret-Reynier MA, Perrocheau G, Piot I, Perol D, Simon G, Lerebours F.
Breast Cancer Res Treat. 2019;173(2):397-406. <https://doi.org/10.1007/s10549-018-5017-2>
6. Survival Impact of Locoregional Treatment of the Primary Tumor in De Novo Metastatic Breast Cancers in a Large Multicentric Cohort Study: A Propensity Score-Matched Analysis.
Pons-Tostivint E, Kirova Y, Lusque A, Campone M, Geffrelot J, Mazouni C, Mailliez A, Pasquier D, Madranges N, Firmin N, Crouzet A, Goncalves A, Jankowski C, De La Motte Rouge T, Pouget N, La Lande B, Mouttet-Boitat D, Ferrero JM, Uwer L, Eymard JC, Mouret-Reynier MA, Petit T, Robain M, Filleron T, Cailliot C, Dalenc F.
Ann Surg Oncol. 2019;26(2):356-65. <https://doi.org/10.1245/s10434-018-6831-9>
7. The ongoing French metastatic breast cancer (MBC) cohort: the example-based methodology of the Epidemiological Strategy and Medical Economics (ESME)
Perol D, Robain M, Arveux P, Mathoulin-Pelissier S, Chamorey E, Asselain B, Berchery D, Gourgou S, Breton M, Delaine-Clisant S, Mons M, Dieras V, Carton M, Guizard AV, Laborde L, Laurent C, Loeb A, Mouret-Reynier MA, Parent D, Perrocheau G, Campion L, Velten M, Cailliot C, Ezzalfani M, Simon G.
BMJ Open. 2019;9(2):e023568. <https://doi.org/10.1136/bmjopen-2018-023568>

Publications 2019 (2/3)

8. Cost-effectiveness of bevacizumab plus paclitaxel versus paclitaxel for the first-line treatment of HER2-negative metastatic breast cancer in specialist oncology centers in France. Petitjean A, Smith-Palmer J, Valentine W, Tehard B, Roze S. BMC Cancer. 2019;19(1):140. <https://doi.org/10.1186/s12885-019-5335-8>
9. Assessment of the efficacy of successive endocrine therapies in hormone receptor-positive and HER2-negative metastatic breast cancer: a real-life multicentre national study. Le Saux O, Lardy-Cleaud A, Frank S, Debled M, Cottu PH, Pistilli B, Vanlemmens L, Leheurteur M, Levy C, Laborde L, Uwer L, D'hont V, Berchery D, Lorgis V, Ferrero JM, Perrocheau G, Courtinard C, Mouret-Reynier MA, Velten M, Breton M, Parent D, Chabaud S, Robain M, Bachelot T. Eur J Cancer. 2019;118:131-41. <https://doi.org/10.1016/j.ejca.2019.06.014>
10. CinéBreast-factors influencing the time to first metastatic recurrence in breast cancer: Analysis of real-life data from the French ESME MBC database. Gougis P, Carton M, Tchokothe C, Campone M, Dalenc F, Mailliez A, Levy C, Jacot W, Debled M, Leheurteur M, Bachelot T, Hennequin A, Perrin C, Goncalves A, Uwer L, Eymard JC, Mouret-Reynier MA, Chamorey E, Dimon G, Saghatchian M, Cailliot C, Le Tourneau C. Breast. 2019;49:17-24. <https://doi.org/10.1016/j.breast.2019.10.004>

Publications 2019 (3/3)

11. Real-life activity of eribulin mesylate among metastatic breast cancer patients in the multicenter national observational ESME program.
Jacot W, Heudel P, Fraisse J, Gourgou S, Guiu S, Dalenc F, Pistilli B, Campone M, Levy C, Debled M, Leheurteur M, Chaix M, Lefevre C, Goncalves A, Uwer L, Ferrero JM, Eymard JC, Petit T, Mouret-Reynier MA, Courtinard C, Cottu P, Robain M, Mailliez A.
Int J Cancer. 2019;145(12):3359-69. <https://doi.org/10.1002/ijc.32402>

12. Impact of breast cancer molecular subtypes on the incidence, kinetics and prognosis of central nervous system metastases in a large multicentre real-life cohort.
Darlix A, Louvel G, Fraisse J, Jacot W, Brain E, Debled M, Mouret-Reynier MA, Goncalves A, Dalenc F, Delalogue S, Campone M, Augereau P, Ferrero JM, Levy C, Fumet JD, Lecouillard I, Cottu P, Petit T, Uwer L, Jouannaud C, Leheurteur M, Dieras V, Robain M, Chevrot M, Pasquier D, Bachelot T.
Br J Cancer. 2019;121(12):991-1000. <https://doi.org/10.1038/s41416-019-0619-y>

Publications 2020 (1/3)

13. Treatment and outcomes in patients with central nervous system metastases from breast cancer in the real-life ESME MBC cohort.
Pasquier D, Darlix A, Louvel G, Fraisse J, Jacot W, Brain E, Petit A, Mouret-Reynier MA, Goncalves A, Dalenc F, Deluche E, Frenel JS, Augereau P, Ferrero JM, Geffrelot J, Fumet JD, Lecouillard I, Cottu P, Petit T, Uwer L, Jouannaud C, Leheurteur M, Dieras V, Robain M, Mouttet-Audouard R, Bachelot T, Courtinard C.
Eur J Cancer. 2020;125:22–30. <https://doi.org/10.1016/j.ejca.2019.11.001>
14. Radiation Therapy to the Primary Tumor for de Novo Metastatic Breast Cancer and Overall Survival in a Retrospective Multicenter Cohort Analysis.
Pons-Tostivint E, Kirova Y, Lusque A, Campone M, Geffrelot J, Rivera S, Mailliez A, Pasquier D, Madranges N, Firmin N, Crouzet A, Goncalves A, Jankowski C, De La Motte Rouge T, Pouget N, De la Lande B, Mouttet-Boizat D, Ferrero JM, Uwer L, Eymard JC, Mouret-Reynier MA, Petit T, Courtinard C, Filleron T, Robain M, Dalenc F.
Radiother and Oncol. 2020;145:109-16. <https://doi.org/10.1016/j.radonc.2019.12.019>
15. Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008-2016.
Deluche E, Antoine A, Bachelot T, Lardy-Cleaud A, Dieras V, Brain E, Debled M, Jacot W, Mouret-Reynier MA, Goncalves A, Dalenc F, Patsouris A, Ferrero JM, Levy C, Lorgis V, Petit T, Uwer L, Jouannaud C, Leheurteur M, Lacroix-Triki M, Courtinard C, Perol D, Robain M, Delalogue S.
Eur J Cancer. 2020;129:60-70. <https://doi.org/10.1016/j.ejca.2020.01.016>

Publications 2020 (2/3)

16. Real-World Evaluation of Oral Vinorelbine in the Treatment of Metastatic Breast Cancer: An ESME-MBC Study.
Heudel P, Delaloge S, Parent D, Madranges N, Levy C, Dalenc F, Brain E, Uwer L, D'hont V, Augereau P, Mailliez A, Perrin C, Frenel JS, Sablin MP, Mouret-Reynier MA, Vermeulin T, Eymard JC, Petit T, Ferrero JM, Ilie S, Goncalves A, Chenuc G, Robain M, Simon G, Perol D. Anticancer Res. 2020;40(7):3905-13. <https://doi.org/10.21873/anticancer.14381>
17. Impact of Age at Diagnosis of Metastatic Breast Cancer on Overall Survival in the Real-Life ESME Metastatic Breast Cancer Cohort.
Frank S, Carton M, Dubot C, Campone M, Pistilli B, Dalenc F, Mailliez A, Levy C, D'hont V, Debled M, Vermeulin T, Coudert B, Perrin C, Goncalves A, Uwer L, Ferrero JM, Eymard JC, Petit T, Mouret-Reynier MA, Patsouris A, Guesmia T, Bachelot T, Robain M, Cottu P. The Breast. 2020;52:50-57. <https://doi.org/10.1016/j.breast.2020.04.009>
18. Palliative Care Delivery According to Age in 12,000 Women with Metastatic Breast Cancer: Analysis in the Multicentre ESME-MBC Cohort 2008–2016.
Frasca M, Sabathe C, Delaloge S, Galvin A, Patsouris A, Levy C, Mouret-Reynier MA, Desmoulins I, Vanlemmes L, Bachelot T, Goncalves A, Perotin V, Uwer L, Frenel JS, Ferrero JM, Bouleuc C, Eymard JC, Dieras V, Leheurteur M, Petit T, Dalenc F, Jaffre A, Chevrot M, Courtinard C, Mathoulin-Pelissier S. Eur J Cancer. 2020;137:240-49. <https://doi.org/10.1016/j.ejca.2020.07.007>

19. Management and Outcome of Male Metastatic Breast Cancer in the National Multicenter Observational Research Program Epidemiological Strategy and Medical Economics (ESME). Sirieix J, Fraise J, Mathoulin-Pelissier S, Leheurteur M, Vanlemmens L, Jouannaud C, Dieras V, Levy C, Ung M, Mouret-Reynier MA, Petit T, Coudert B, Brain E, Pistilli B, Ferrero JM, Goncalves A, Uwer L, Patsouris, Tredan O, Courtinard C, Gourgou S, Frenel JS. Ther Adv Med Oncol 2020;12. <https://doi.org/10.1177/1758835920980548>

Publications 2021 (1/4)

20. Real-Life Prognosis of 5041 Bone-Only Metastatic Breast Cancer Patients in the Multicenter National Observational ESME Program.
Bertho M, Fraisse J, Patsouris A, Cottu P, Arnedos M, Perol D, Jaffre A, Goncalves A, Lebitasy MP, D'hont V, Dalenc F, Ferrero JM, Levy C, Dabakuyo S, Rouzier R, Penault-Llorca F, Uwer L, Eymard JC, Breton M, Chevrot M, Thureau S, Petit T, Simon G, Frenel JS.
Ther Adv Med Oncol. 2021;13. <https://doi.org/10.1177/1758835920987657>
21. Early Locoregional Breast Surgery and Survival in de novo Metastatic Breast Cancer in the Multicenter National ESME Cohort.
Hotton J, Lusque A, Leufflen L, Campone M, Levy C, Honart JF, Mailliez A, Debled M, Gutowski M, Leheurteur M, Goncalves A, Jankowski C, Guillermet S, Bachelot T, Ferrero JM, Eymard JC, Petit T, Pouget N, De la Lande B, Frenel JS, Villacroux O, Simon G, Pons-Tostivint E, Marchal F.
Ann Surg. 2021;277(1):e153-61. <https://doi.org/10.1097/sla.0000000000004767>
22. Impact of body mass index on overall survival in patients with metastatic breast cancer.
Salah K, Carton M, Dieras V, Heudel P-E, Brain E, D'hondt V, Mailliez A, Patsouris A, Mouret-Reynier MA, Goncalves A, Ferrero JM, Petit T, Emile G, Uwer L, Debled M, Dalenc F, Jouannaud C, Ladoire S, Leheurteur M, Cottu P, Veron L, Savignoni A, Courtinard C, Robain M, Delalogue S, Deluche E.
Breast. 2021;55:16–24. <https://doi.org/10.1016/j.breast.2020.11.014>

Publications 2021 (2/4)

23. Outcome beyond third-line chemotherapy for metastatic triple negative breast cancer in the French ESME program.
Cabel L, Carton M, Pistilli B, Dalenc F, Vanlemmens L, Levy C, Jacot W, Debled M, Loeb A, Hennequin A, De La Motte Rouge T, Laborde L, Laurent C, Chalorey E, Parent D, Petit T, Mouret-Reynier MA, Campone M, Perrocheau G, Labreveux C, Bachelot T, Robain M, Lerebours F.
The Breast. 2021; 56:18-25. <https://doi.org/10.1016/j.breast.2021.01.006>
24. Phenotypic Discordance between Primary and Metastatic Breast Cancer in the Large-Scale Real-Life Multicenter French ESME Cohort.
Grinda T, Joyon N, Lusque A, Lefèvre S, Arnould L, Penault-Llorca F, Macgrogan G, Treilleux I, Vincent-Salomon A, Haudebourg J, Maran-Gonzales A, Charafe-Jauffret E, Courtinard C, Franchet C, Verrielle V, Brain E, Tas P, Blanc-Fournier C, Leroux A, Lousouarn D, Berghian A, Brabencova E, Ghassia JP, Scoazec JY, Delalogue S, Filleron T, Lacroix-Tikri M.
NPJ Breast Cancer. 2021;7(1):41. <https://doi.org/10.1038/s41523-021-00252-6>
25. Breast cancer patients treated with intrathecal therapy for leptomeningeal metastases in a large real-life database.
Carausu M, Carton M, Darlix A, Pasquier D, Leheurteur M, Debled M, Mouret-Reynier MA, Goncalves A, Dalenc F, Verret B, Campone M, Augereau P, Ferrero JM, Levy C, Fumet JD, Lefeuvre-Plesse C, Petit T, Uwer L, Jouannaud C, Larrouquere L, Chevrot M, Courtinard C, Cabel L.
ESMO Open. 2021;6(3):100150. <https://doi.org/10.1016/j.esmoop.2021.100150>

Publications 2021 (3/4)

26. Evolution of overall survival and receipt of new therapies by subtype among 20 446 metastatic breast cancer patients in the 2008-2017 ESME cohort.
Grinda T, Antoine A, Jacot W, Blaye C, Cottu PH, Diéras V, Dalenc F, Goncalves A, Debled M, Patsouris, Mouret-Reynier MA, Mailliez A, Clatot F, Levy C, Ferrero JM, Desmoulins I, Uwer L, Petit T, Jouannaud C, Lacroix-Tokri M, Deluche E, Robain M, Courtinard C, Bachelot T, Brain E, Perol D, Delalogue S.
ESMO Open. 2021;6(3):100114. <https://doi.org/10.1016/j.esmoop.2021.100114>
27. Metastatic inflammatory breast cancer: survival outcomes and prognostic factors in the national and real-life French cohort (ESME).
Dano D, Lardy-Cléaud A, Monneur A, Quenel-Tueux N, Levy C, Mouret-Reynier MA, Coudert B, Mailliez A, Ferrero JM, Guiu S, Campone M, De La Motte Rouge T, Petit T, Pistilli B, Dalenc F, Simon G, Lerebours F, Chabaud S, Bertucci F, Goncalves A.
ESMO Open. 2021;6(4):100220. <https://doi.org/10.1016/j.esmoop.2021.100220>
28. Addressing the Issue of Bias in Observational Studies: Using Instrumental Variables and a Quasi-Randomization Trial in an ESME Research Project.
Ezzalfani M, Porcher R, Savignoni A, Delalogue S, Filleron T, Robain M, Perol D, ESME Group.
PLoS One. 2021;16(9): e0255017. <https://doi.org/10.1371/journal.pone.0255017>

Publications 2021 (4/4)

29. De Novo Metastatic Breast Cancer in Patients with a Small Locoregional Tumour (T1-T2/N0): Characteristics and Prognosis.
Gaillard T, Carton M, Mailliez A, Desmoulins I, Mouret-Reynier MA, Petit T, Leheurteur M, Dieras V, Ferrero JM, Uwer L, Guiu S, Goncalves A, Levy C, Debled M, Dalenc F, Patsouris A, Bachelot T, Eymard JC, Chevrot M, Conversano A, Robain M, Hequet D.
Eur J Cancer. 2021; 158:181-8. <https://doi.org/10.1016/j.ejca.2021.09.021>
30. Treatment and outcomes of older versus younger women with HER2-positive metastatic breast cancer in the multicenter national observational ESME database.
Annonay M, Gauquelin L, Geiss R, Ung M, Cristol-Dalstein L, Mouret-Reynier MA, Goncalves A, Abadie-Lacourtoisie S, François E, Perrin C, Le Fel J, Lorgis V, Servent V, Uwer L, Jouannaud C, Leheurteur M, Joly F, Champion L, Courtinard C, Villacroux O, Petit T, Soubeyran P, Terret C, Bellera C, Brain E, Delaloge S.
The Breast. 2021;60:138-46. <https://doi.org/10.1016/j.breast.2021.09.011>
31. Progression free survival on endocrine therapy, before or after chemotherapy, in hormone receptor-positive HER2-negative metastatic breast cancer
Corboux P, Lardy-Cleaud A, Alexandre M, Fontanilles M, Lévy C, Viansone A, Mailiez A, Debled M, Goncalves A, Le Du F, Lerebours F, Ferrero JM, Eymard JC, Mouret-Reynier MA, Petit T, Frenel JS, Dalenc F, Courtinard C, Chaix M, Bachelot T
Breast Cancer Res Treat. 2021 <https://doi.org/10.1007/s10549-021-06382-6>

Publications 2022 (1/3)

32. Real-World Evidence of the Management and Prognosis of Young Women (≤ 40 Years) with de Novo Metastatic Breast Cancer.
Mallet A, Lusque A, Levy C, Pistilli B, Brain E, Pasquier D, Debled M, Thery JC, Goncalves A, Desmoulins I, De la Motte Rouge T, Faure C, Ferrero JM, Eymard JC, Mouret-Reynier MA, Patsouris A, Cottu P, Dalenc F, Petit T, Payen O, Uwer L, Guiu S, Frenel JS.
Ther Adv Med Oncol. 2022;14. <https://doi.org/10.1177/17588359211070362>
33. Clinicopathological Characteristics and Prognosis of Breast Cancer Patients with Isolated Central Nervous System Metastases in the Multicentre ESME Database.
Carausu M, Carton M, Cabel L, Patsouris A, Levy C, Verret B, Pasquier D, Debled M, Goncalves A, Desmoulins I, Lecouillard I, Bachelot T, Ferrero JM, Eymard JC, Mouret-Reynier MA, Chevrot M, De Maio E, Uwer L, Frenel JS, Leheurteur, Petit T, Darlix A, Bozec L.
Ther Adv Med Oncol. 2022;14. <https://doi.org/10.1177%2F17588359221077082>
34. Enrollment of Older Metastatic Breast Cancer Patients in First-Line Clinical Trials: 9-Year Experience of the Large-Scale Real-Life Multicenter French ESME Cohort.
Bringuier M, Carton M, Levy C, Patsouris A, Pasquier D, Debled M, Rigal O, Jacot W, Goncalves A, Desmoulins I, De la Motte Rouge T, Bachelot T, Ferrero JM, Eymard JC, Ung M, Mouret-Reynier MA, Petit T, Chevrot M, Uwer L, Courtinard C, Frenel JS, Vianzone A, Baldini C
Breast Can Res Treat. 2022;191(3):577-87. <https://doi.org/10.1007/s10549-021-06467-2>

Publications 2022 (2/3)

35. Impact of Lobular versus Ductal Histology on Overall Survival in Metastatic Breast Cancer: A French Retrospective Multicentre Cohort Study.
Dalenc F, Lusque A, De La Motte Rouge T, Pistilli B, Brain E, Pasquier D, Debled M, Thery JC, Goncalves A, Desmoulins I, Levy C, Uwer L, Ferrero JM, Eymard JC, Mouret-Reynier MA, Patsouris A, Frenel JS, Petit T, Chevrot M, Bachelot T, Guiu S.
Eur J Cancer. 2022;164: 70–9. <https://doi.org/10.1016/j.ejca.2021.12.031>
36. Efficacy of trastuzumab emtansine (T-DM1) and lapatinib after dual HER2 inhibition with trastuzumab and pertuzumab in patient with metastatic breast cancer: Retrospective data from a French multicenter real-life cohort.
Moinard-Butot F, Saint-Martin C, Pflumio C, Carton M, Jacot W, Cottu PH, Dieras V, Dalenc F, Goncalves A, Debled M, Patsouris A, Mouret-Reynier MA, Vanlemmens L, Leheurteur M, Emile G, Ferrero JM, Desmoulins I, Uwer L, Eymard JC, Cheaib B, Courtinard C, Bachelot T, Chevrot M, Petit T.
The Breast. 2022;164:70–9. <https://doi.org/10.1016/j.ejca.2021.12.031>
37. Comparison of Management and Outcomes in ERBB2-Low vs ERBB2-Zero Metastatic Breast Cancer in France.
De Calbiac O, Lusque A, Maillez A, Bachelot T, Uwer L, Mouret-Reynier MA, Emile G, Jouannaud C, Goncalves A, Patsouris A, Dieras V, Leheurteur M, Petit T, Cottu P, Ferrero JM, D’hont V, Desmoulins I, Mourato-Ribeiro J, Martin AL, Frenel JS
JAMA Network Open. 2022;5(9):e2231170.
<https://doi.org/10.1001/jamanetworkopen.2022.31170>

Publications 2022 (3/3)

38. Efficacy of taxane rechallenge in early metastatic relapse of HER2-negative breast cancer patients previously treated with taxane.
Vasseur A, Carton M, Guiu S, Augereau P, Uwer L, Mouret-Reynier MA, Levy C, Eymard JC, Ferrero JM, Leheurteur M, Goncalves A, Robert M, De la Motte Rouge T, Bachelot T, Petit T, Debled M, Grinda T, Desmoulins I, Vanlemmens L, Nicolai V, Simon G, Cabel L.
The Breast. 2022;65:136-44. <https://doi.org/10.1016/j.breast.2022.07.014>
39. Outcomes of patients with HER2-negative metastatic breast cancer after platinum- and non-platinum-based first-line chemotherapy among patients with and without pathogenic germline BRCA1/2 mutations.
Jacot W, Lusque A, Vicier C, Mailliez A, De la Motte Rouge T, Cabel L, Levy C, Patsouris A, Desmoulins I, Uwer L, They JC, Robain M, Caron O, Tredan O, Filleron T, Frenel JS, Delalogue S.
Br J Cancer. 2022;127(11):1963-73. <https://doi.org/10.1038/s41416-022-02003-1>
40. Association of Endocrine Therapy for HR+/ERBB2+ Metastatic Breast Cancer With Survival Outcomes.
Carausu M, Carton M, Dieras V, Petit T, Guiu S, Goncalves A, Augereau P, Ferrero JM, Levy C, Ung M, Desmoulins I, Debled M, Bachelot T, Pistilli B, Frenel JS, Mailliez A, Chevrot M, Cabel L.
JAMA Network Open. 2022;5(12):e2247154.
<https://doi.org/10.1001/jamanetworkopen.2022.47154>

Publications 2023 (1/3)

41. Long-Term Results with Everolimus in Advanced Hormone Receptor Positive Breast Cancer in a Multicenter National Real-World Observational Study.
François-Martin H, Lardy-Cléaud A, Pistilli B, Levy C, Dieras V, Frenel JS, Guiu S, Mouret-Reynier MA, Mailliez A, Eymard JC, Petit T, Ung M, Desmoulins I, Augereau P, Bachelot T, Uwer L, Debled M, Ferrero JM, Caltot F, Goncalves A, Chevrot M, Chabaud S, Cottu P. Cancer. 2023;15(4):1191. <https://doi.org/10.3390/cancers15041191>
42. Survival outcome of metastatic breast cancer patients by germline BRCA1/2 status in a large multicenter real-world database.
Mailliez A, D'hont V, Lusque A, Caron O, Cabel L, Goncalves A, Debled M, Gladiéff L, Ferrero JM, Petit T, Mouret-Reynier MA, Eymard JC, Levy C, Uwer L, Leheurteur M, Desmoulins I, Bachelot T, Frenel JS, De la Motte Rouge T, Simon G, Jacot W, Delalogue S. Int J Cancer. 2023;152(5):921-31. <https://doi.org/10.1002/ijc.34304>
43. Clinical outcome of patients with isolated central nervous system progression on first-line Pertuzumab and Trastuzumab treatment for HER2-positive metastatic breast cancer in real life cohort.
Collet L, Eberst L, Gauthier L, Debled M, Hrab I, Mouret-Reynier MA, Desmoulins I, Goncalves A, Campone M, Ferrero JM, Brain E, Uwer L, Eymard JC, Dieras V, Simon G, Leheurteur M, Dalenc F, Vanlemmens L, Darlix A, Arnedos M, Bachelot T. Breast Cancer. 2023;30(2):329-41. <https://doi.org/10.1007/s12282-022-01427-0>

Publications 2023 (2/3)

44. Association between progression-free survival and overall survival in women receiving first-line treatment for metastatic breast cancer: evidence from the ESME real-world database.
Courtinard C, Gourgou S, Jacot W, Carton M, Guérin O, Vacher L, Bertaut A, Le Deley MC, Perol D, Marino P, Levy C, Uwer L, Perrocheau G, Schiappa R, Bachelot F, Parent D, Breton M, Petit T, Filleron T, Loeb A, Mathoulin-Pelissier S, Robain M, Delalogue S, Bellera C.
BMC Med. 2023;21(1):87 <https://doi.org/10.1186/s12916-023-02754-5>
45. Efficacy of front-line treatment for hormone receptor-positive HER2-negative metastatic breast cancer with BRCA1/2 mutation.
Frenel JS, Lusque A, Delalogue S, Ferrero JM, Bachelot T, Desmoulins I, Levy C, Eymard JC, Goncalves A, Patsouris A, Mouret-Reynier MA, Thery JC, Petit T, Cabel L, Uwer L, Chevrot M, Mailliez A, Jacot W, De la Motte Rouge T.
Br J Cancer. 2023;128(11):2072-80. <https://doi.org/10.1038/s41416-023-02248-4>
46. Target trial emulation to assess real-world efficacy in the Epidemiological Strategy and Medical Economics metastatic breast cancer cohort.
Antoine A, Pérol D, Robain M, Delalogue S, Lasset C, Drouet Y.
JNCI. 2023;115(8):971-80. <https://doi.org/10.1093/jnci/djad092>

Publications 2023 (3/3)

47. Real-world clinical and survival outcomes of patients with early relapsed triple-negative breast cancer from the ESME national cohort.
Grinda T, Antoine A, Jacot W, Cottu PH, De la Motte Rouge T, Frenel JS, Mailliez A, Dalenc F, Goncalves A, Clatot F, Mouret-Reynier MA, Levy C, Ferrero JM, Desmoulins I, Uwer L, Petit T, Jouannaud C, Arnedos M, Chevrot M, Courtinard C, Tredan O, Brain E, Perol D, Pistilli B, Delalogue S.
Eur J Cancer. 2023;1189:112935 <https://doi.org/10.1016/j.ejca.2023.05.023>
48. Real-world impact of adjuvant anti-HER2 treatment on characteristics and outcomes of women with HER2-positive metastatic breast cancer in the ESME program.
Le Du F, Carton M, Bachelot T, Saghatchian M, Pistilli B, Brain E, Loirat D, Vanlemmens L, Vermeuin T, Emile G, Goncalves A, Ung M, Robert M, Jaffre A, Desmoulins I, Jouannaud C, Uwer L, Ferrero JM, Mouret-Reynier MA, Jacot W, Chevrot M, Delalogue S, Dieras V.
The Oncologist. 2023;137 <https://doi.org/10.1093/oncolo/oyad137>

Publications 2024 (1/2)

49. First-line real-world treatment patterns and survival outcomes in women younger or older than 40 years with metastatic breast cancer in the real-life multicenter French ESME cohort. Galvin A, Courtinard C, Bouteiller F, Gourgou S, Dalenc F, Jacot W, Arnedos M, Bailleux C, Dieras V, Petit T, Emile G, Dubray-Longeras P, Frenel JS, Bachelot T, Mailliez A, Brain E, Desmoulins I, Massard V, Patsouris A, Goncalves A, Grinda T, Delalogue S, Bellera C. Eur J Cancer. 2023;196 <https://doi.org/10.1016/j.ejca.2023.113422>
50. Incidence and outcome of brain and/or leptomeningeal metastases in HER2-low metastatic breast cancer in the French ESME cohort. Epaillard N, Lusque A, Jacot W, Mailliez A, Bachelot T, Arnedos M, Dieras V, Brain E, Ferrero JM, Massard V, Desmoulins I, Mouret-Reynier MA, Levy C, Goncalves A, Leheurteur M, Petit T, Filleron T, Bosquet L, Pistilli B, Frenel JS. ESMO Open. 2024 <https://doi.org/10.1016/j.esmoop.2024.103447>
51. Real-world effectiveness of post-trastuzumab emtansine treatment for human epidermal growth factor receptor 2-positive metastatic breast cancer: a multicenter, multicohort analysis from the Epidemiology Strategy and Medical Economics database (2008-2018) Courtinard C, Barbet V, Schiappa R, Pilleul F, Michiels S, Dabakuyo S, Gourgou S, Jaffre A, Asselain B, Bosquet L, Dunton K, Rosenlund M, Liang Z, Cathcart J, Delalogue S. Real-World Data and Digital Oncology. 2024 <https://doi.org/10.1016/j.esmorw.2024.100043>

Publications 2024 (2/2)

52. Assessing the real-world effectiveness of 8 major metastatic breast cancer drugs using target trial emulation

Antoine A, Pérol D, Robain M, Bachelot T, Choquet R, Jacot W, Yahia BBH, Grinda T, Delalogue S, Lasset C, Drouet Y

Eur J Cancer. 2024 <https://doi.org/10.1016/j.ejca.2024.115072>

Publications 2025

53. Real world treatment patterns and effectiveness after disease progression on CDK4/6 inhibitors for HR+/HER2- metastatic breast cancer in the ESME-MBC cohort
Varnier R, Pérol D, Jacot W, Mailliez A, Diéras V, Dalenc F, Gonçalves A, Levy C, Arnedos M, Frenel JS, Bailleux C, Massard V, Brain E, Sauterey B, Savoye AM, They JC, Petit T, Bachelot T, Thomas Grinda T, Ray-Coquard I
ESMO Open. 2025 <https://doi.org/10.1016/j.esmoop.2025.105803>
54. Transportability of overall survival estimates from the USA to France in patients with metastatic triple-negative breast cancer
Esnault C, Simomia L, Machuron G, Robain M, Adamson B, Machuron V
ESMO Real Worl Data and Digital Oncol. 2025 <https://doi.org/10.1016/j.esmorw.2025.100648>
55. Recent treatment and survival trends in older versus younger women with HR-positive HER2-negative metastatic breast cancer in the real-life multicenter French ESME cohort
Bouteiller F, Gourgou S, Binguier M, Galvin A, Mailliez A, Bertrand N, Hung M, Frenel JS, Massard V, Bachelot T, Pflumio C, Gonçalves A, Levy C, Bosquet L, Jacot W, Delaloge S, Grinda T, Bellera C
Eur J Cancer. 2025 <https://doi.org/10.1016/j.ejca.2025.116166>

Publications 2026

56. BRCA1/2 or PALB2 mutations and efficiency of first line CDK4/6 inhibitors in Hormone Receptor-positive metastatic breast cancer
Guinel T, Lusque A, Mailliez A, Massard V, Jacot W, Guiu S, De la Motte Rouge T, Brain E, Desmoulins I, Arnedos M, Bailleux, C, Gonçalves A, Levy C, Bachelot T, Bosquet L, Delalogue S, Frenel JS
The Breast. 2026;86. <https://doi.org/10.1016/j.breast.2026.104739>
57. Characteristics and outcomes of patients with HER2-negative metastatic breast cancers with low expression of estrogen and progesterone receptors in the multicenter ESME cohort
Alexandre M, Teruel E, Dalenc F, De la Motte Rouge T, Brain E, Massard V, Arnedos Mailliez A, Ferrero JM, Bachelot T, Desmoulins I, Mouret-Reynier MA, Levy C, Gonçalves A, Berghian A, Petit T, Frenel JS, Martin AL, Delalogue S, Jacot W
The Breast. 2026;88 <https://doi.org/10.1016/j.breast.2026.104815>
58. Characteristics, treatment and survival of older patients with metastatic triple negative breast cancer from the ESME mBC real-world national cohort: a comparison with younger women
Mairé M, Bouteiller F, Chakiba C, jacot W, Geiss R, Ung M, Goncalves A, Frenel JS, Bailleux C, Perrin C, Massard V, Mailliez A, Jouannaud C, Cherifi F, Petit T, Terret C, Viansone A, Bosquet L, Galvin A
The Breast. 2026;88 <https://doi.org/10.1016/j.breast.2026.104816>